中国麻风皮肤病杂志 ›› 2024, Vol. 40 ›› Issue (2): 95-100.doi: 10.12144/zgmfskin202402095

• 论著 • 上一篇    下一篇

浓缩生长因子治疗雄激素性秃发的回顾性研究

刘燕1,2，3*,庞静1，2*,张雪青1，2,刘建新1，2,董璐1，2,李建可1，2,王秀环1，2,刘鑫洲1，2,刘国艳1，2   

  1. 1山东第一医科大学附属皮肤病医院，山东济南，250022；2山东省皮肤病性病防治研究所，山东济南，250022；3山东中医药大学，山东济南，250014
    *共同第一作者
  • 出版日期:2024-02-15 发布日期:2024-01-30

Concentrated growth factor for the treatment of androgenetic alopecia: a retrospective study

LIU Yan1，2,3*, PANG Jing1，2*, ZHANG Xueqing1,2, LIU Jianxin1,2, DONG Lu1,2, LI Jianke1,2, WANG Xiuhuan1,2, LIU Xinzhou1,2, LIU Guoyan1,2   

  1. 1 Hospital for Skin Diseases, Shandong First Medical University, Jinan 250022, China; 2 Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan 250022, China; 3 Shandong University of Traditional Chinese Medicine, Jinan 250014, China
    *Co-first author
  • Online:2024-02-15 Published:2024-01-30

PDF (PC)

136

摘要： 目的：回顾性分析浓缩生长因子（concentrated growth factor，CGF）治疗雄激素性秃发（androgenetic alopecia，AGA）的疗效与安全性。方法：收集使用CGF治疗的60例AGA患者资料。12例为CGF治疗组，48例为联合治疗组。CGF组和联合治疗组均给予CGF治疗，连续注射3次，联合组另给予米诺地尔酊外用，口服非那雄胺(男性)或螺内酯(女性)。通过毛发密度和毛囊单位密度改善程度、毛发镜图像特征变化、治疗前后照片以及医生和患者满意度评价综合评估有效性。同时，记录发生局部及全身不良反应的患者例数，以评估安全性。结果：CGF联合治疗组和CGF组治疗后的平均毛囊单位密度较治疗前分别增加了(18.04±11.15)和(8.81±5.77)个/cm2（均P<0.05），平均毛发密度较治疗前分别增加了(36.43±21.18)和(16.19±12.62)根/cm2 (均P<0.05)。两组之间在改善毛发密度上差异具有统计学意义（P<0.05），在改善毛囊单位密度上差异无统计学意义（P＞0.05）。两组毛囊周围褐色征、黄点征、空毛囊的治疗后改善率均在70%以上，但两组之间差异均无统计学意义（均P＞0.05）。两组医生与患者治疗后满意率均在90%以上。60例患者中仅有2例局部注射部位疼痛明显，3例患者头皮瘙痒。结论：CGF治疗AGA安全有效，联合使用米诺地尔酊和非那雄胺/螺内酯，效果更佳。

关键词: 浓缩生长因子, 雄激素性秃发, 毛发再生

Abstract: Objective: To retrospectively analyze clinical efficacy and safety of concentrated growth factor（CGF）in the treatment of androgenetic alopecia （AGA). Methods: Sixty patients with moderate-to-severe AGA were collected including 48 in combination therapy group and 12 in CGF therapy group. All the patients were treated with AGA, once a month, for 3 times, and the patients in the combination therapy group were given additional topical minoxidil tincture, oral finasteride for male and spironolactone for female. The efficacy of the treatment were evaluated through the hair density and follicle unit density, the characteristics of the trichoscopic images, digital photographs and the global aesthetic improvement scale (GIAS). In addition, the number of patients with localized and systemic adverse reactions were recorded to assess the safety of the treatment. Results: Compared to pre-treatment, the mean follicle unit density in the CGF combination treatment group and CGF treatment group increased by 18.04±11.15 and 8.81±5.77 follicles/cm2 after treatment (Ps<0.05), and the hair density increased by 36.43±21.18 and 16.19±12.62 roots/cm2 (Ps<0.05). There was a significant difference in hair density  between the two groups (P<0.05), but there was no significant difference in follicle unit density improvement (P＞0.05). The improvement rates of perifollicular brown sign, yellow dot sign, and empty hair follicles were more than 70% in both groups , but none of the differences between the two groups were statistically significant. Both physician and patient satisfaction rates were upwards of 90% in two groups after the treatment. Only 2 of the 60 patients had obvious pain at the local injection area, and 3 experienced scalp itching. Conclusion: CGF is a safe and effective method for the treatment of androgenic alopecia, and the combined use of minoxidil tincture and finastericle or spironolactone is more effective.

Key words: concentrated growth factor, androgenetic alopecia, hair regrowth